The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Colorectal cancer at ASCO 2024: COLLISION, TRANSMET & ORCHESTRA
Major Lee, MD, PhD, The University of Pennsylvania, Pittsburgh, PA, discusses findings from the Phase III COLLISION trial (NCT03088150), of surgery versus thermal ablation for small-size colorectal liver metastases, as well as the TRANSMET trial (NCT02597348), which assessed chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases. Dr Lee additionally gives an overview of the Phase III ORCHESTRA trial (NCT01792934), which demonstrated that additional tumor debulking to first-line palliative systemic therapy did not improve overall survival for patients with multiorgan metastatic colorectal cancer. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
